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Abstract
Background: Nasopharyngeal carcinoma (NPC) is a human epithelial tumour with high prevalence amongst Chinese in
Southern China and South East Asia and is associated with the Epstein-Barr virus (EBV). The viral genome harbours an
oncogene, namely, the latent membrane protein 1 (LMP1) gene and known variants such as the 30-bp deletion and loss
of XhoI restriction site have been found. Less is known about the relationship between these variants and the population
characteristics and histological type.
Methods: In this study, the EBV LMP1 gene variants from 42 NPC and 10 non-malignant archived formalin fixed, paraffin-
embedded tissues, as well as plasma from another 35 patients with nasopharyngeal carcinoma were determined by using
Polymerase Chain Reaction (PCR). Statistical analysis was performed by using SPSS programme.
Results: LMP1 30-bp deletion was detected in 19/34 (55.9%) of NPC tissues, 7/29 (24.1%) of plasma but absent in non-
malignant tissues (8/8). Coexistence of variants with and without 30bp deletion was found only in 5/29 (17.2%) plasma
samples but not in NPC tissues. The loss of XhoI restriction site in LMP1 gene was found in 34/39 (87.2%) of the NPC
tissues and 11/30 (36.7%) of plasma samples. None of the non-malignant nasopharyngeal tissues (8/8) harbour XhoI-loss
variants. LMP1 30-bp deletion was detected in 16/18 Chinese versus 3/15 Malays and 13/16 type III (undifferentiated
carcinoma) versus 1/6 type I (keratinizing squamous cell carcinoma). XhoI-loss was found in 19/19 Chinese versus 14/19
Malays and 18/18 type III (undifferentiated) versus 2/5 type I (keratinizing squamous cell carcinoma). Statistical analysis
showed that these variants were associated with ethnic race (30-bp deletion, p < 0.05; XhoI-loss, p = 0.046) and
histological type of NPC (30-bp deletion, p = 0.011; XhoI-loss, p = 0.006). Nineteen out of 32 NPC tissues (19/32; 59.4%)
and 6/24 (25%) of plasma samples showed the coexistence of both the 30-bp deletion and the loss of XhoI restriction
site. A significant relationship was found with the Chinese race but not histological type.
Conclusion: The incidence rate of 56% for LMP1 30-bp deletion was lower compared to previously reported rates of
75–100% in NPC tissues. Coexistence of variants with and without 30-bp deletion was found only in 5/29 plasma samples.
The incidence rate of XhoI restriction site loss in NPC was comparable to other studies from endemic regions such as
Southern China. For the first time, the presence of LMP1 30-bp deletion or XhoI-loss was associated with the Chinese
race and type III NPC. Both these variants were not found in non-malignant tissues. The influence of these variants on
disease progression and outcome in Chinese and type III NPC requires further investigation.
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Background
Nasopharyngeal carcinoma (NPC) is a tumour arising
from epithelial cells of the nasopharynx. The neoplasm is
uncommon in most countries with age-adjusted inci-
dence for both sexes of less than one per 100,000 popula-
tions [1]. However, NPC is endemic in southern China
where it is the third most common form of malignancy
amongst men, with incidence rates of between 15 and 50
per 100,000 [2]. In Malaysia, it is also the second most
common cancer among males in Malaysia which consti-
tutes 8.8% of total male cancers [3] with incidence rates of
18.1 and 7.4 per 100,000 populations for Chinese males
and females, respectively. Lower rates of 7%, 1.5% and
2.6% were reported for Malay males, Malay females and
Indian males, respectively. About 81% of the cases diag-
nosed were at advanced stage of the disease [4].
A unique feature of NPC is its strong association with
Epstein-Barr virus (EBV). EBV DNA is consistently
detected in patients with almost all nasopharyngeal can-
cers from regions of high and low incidence. EBV has been
found to be present in all the NPC samples by various
techniques such as PCR, in situ hybridization and immu-
nohistochemistry staining [5]. Latent EBV infection has
been shown to be an early event in the development of the
cancer [6]. Among the latent gene products encoded by
EBV, latent membrane protein 1 (LMP1) is particularly
interesting because it displays classic oncogenic ability in
rodent fibroblast transformation [7,8] and it is capable of
inducing a range of phenotypic changes in both B cells
and epithelial cells [9]. The importance of LMP1 in tum-
origenesis of NPC in vivo is supported by the finding that
LMP1 was expressed in 78% NPC samples [10]. The
region of LMP1 thought to be important for oncogenesis
is the C-terminus which is a hot spot region for mutations
[11]. Deletion of a 30-bp sequence in the LMP1 gene
results in progression from a non-oncogenic to an onco-
genic state. Restoration of the 30-bp sequence reversed the
transformation ability [12]. The 30-bp deletion has been
found in Hodgkin's disease (HD) [13], human immuno-
deficiency virus-related HD cases [14], Malaysian and
Danish post-transplant lymphoproliferative diseases
(PTLs) [13], nasal T/natural killer (NK)-cell lymphoma
[15], Burkitt's lymphoma and non-Hodgkin's diseases
[16]. The 30-bp deletion has also been shown to result in
a more aggressive phenotype of EBV-associated lympho-
proliferative disease and lymphoma in vivo [17].
Other mutations that have been identified in LMP1 gene
include a point mutation at nucleotide position 169425
(G → T) resulting in loss of XhoI restriction site in exon 1,
and multiple point mutations [18]. The XhoI polymor-
phism was also present in all NPC from Alaska and in
some of the NPC samples from Caucasian Americans but
was absent in the Africa's NPC and healthy controls
[19,20]. These variations are represented in the well-stud-
ied EBV strains namely, CAO and C1510 [18,21]. It has
been suggested that these changes in both CAO and
C1510 are associated with increased tumorigenicity in
SCID and nude mice [22]. The XhoI polymorphism has
been found in EBV isolates in HD [23], nasal and periph-
eral T-cell lymphoma (NPTL) and infectious mononucle-
osis (IM) [24].
There are only a few reports on the association of these
variants with clinicopathological data in NPC. The pres-
ence of the 30-bp deletion was strongly associated with
non-keratinizing carcinoma type of NPC in one study
[25]. However, no statistical significance in age, gender,
radiosensitivity and pathological classification was
reported in another study [26]. A study by Tan et al. [27],
showed the coexistence of the wild type and 30-bp dele-
tion in NPC biopsies but no correlation with clinico-
pathological data was made.
Hence, to date, the correlation between the co-existence of
the LMP-1 30-bp deletion and loss of XhoI restriction site
variants in either NPC tissue or plasma with clinicopatho-
logical data has not yet been studied. The objectives of our
study was to determine the relationship between the LMP-
1 variants with 30-bp deletion and/or loss of XhoI restric-
tion site as well as the co-existence of these variants in
NPC tissues and plasma with population characteristics
and histological type.
Methods
Sample collection
A total of 42 NPC and 10 non-malignant nasopharyngeal
formalin-fixed paraffin embedded tissue were used for
this study. The non-malignant tissues were obtained from
patients with suspected cases of NPC but were confirmed
to be normal by histology. Sections of 4 μm thickness
were cut from each tissue blocks. The specimens were his-
tologically classified into three types according to World
Health Organization (WHO) classification: Keratinizing
squamous cell carcinoma (SCC, Type I), non-keratinizing
carcinoma (NKC, Type II), and undifferentiated carci-
noma (UC, Type III).
Blood samples were collected from another group of 35
patients with histopathologically confirmed NPC at Hos-
pital Kuala Lumpur (HKL) from June 2006 to April 2007.
Approximately 5 ml of peripheral blood was collected
into a tube containing EDTA anticoagulant. EBV was
recovered from the supernatant above the mononuclear
cell layer after Ficoll-hypaque centrifugation at 2500 rpm
for 20 minutes and frozen at -80°C until further process-
ing. This supernatant was referred to as "plasma".World Journal of Surgical Oncology 2008, 6:18 http://www.wjso.com/content/6/1/18
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Ethics approval was obtained from the Ministry of Health
Ethics Committee and Faculty of Medicine and Health
Sciences, University Putra Malaysia Ethics Committee for
this study.
Cell culture
Cell line B95.8 was used as a positive control. The B95.8
cell line was grown in 37°C, 5% carbon dioxide (CO2),
95% humidifying air incubator and cultured with com-
plete RPMI 1640 medium (GIBCO, USA) supplemented
with 2mM L-glutamine, 100 IU/ml penicillin, 100 μg/ml
streptomycin, 0.5 μg/ml Fungizone, 0.1 μg/ml Gentamy-
cin (GIBCO, USA), 2.0 g/L sodium bicarbonate (Sigma,
USA) and 10% foetal bovine serum (FBS) (GIBCO, USA).
The cells were grown until 70% to 90% confluence before
being harvested.
DNA extraction
DNA from cell culture and paraffin-embedded tissue were
extracted by using the GENE ALL™ Tissue SV (plus) mini
kit (General Biosystem, Korea). An extra step of deparaffi-
nization with xylene was performed for the tissues. Abso-
lute ethanol was added to the cell pellet to remove the
residual xylene and then air-dried. The tissue pellet was
resuspended in 180 μl Tissue Lysis solution and digested
overnight with 20 μl of 20 mg/ml Proteinase K at 56°C.
Three μl of 20 mg/ml RNase A solution (Amresco, Ohio)
was added, mixed thoroughly and incubated at room tem-
perature to obtained an RNA-free DNA. Four hundred μl
Tissue Binding Solution was added and the mixture was
transferred to the spin column and centrifuged for 1 min
at 10,000 rpm. Purification of DNA was performed
according to manufacturer's operating instructions.
Plasma DNA was extracted using the GENE ALL™ Blood
SV mini kit (General Biosystem, Korea). A total of 800 μl
of plasma samples were used for DNA extraction per col-
umn. 80 μl of 20mg/ml Proteinase K solution (General
Biosystem, Korea) and 3 μl of 20mg/ml RNase A
(Amresco, Ohio) were added and incubated for 15 min at
room temperature. Eight hundred μl of blood lysis buffer
was added and mixed thoroughly by vortexing followed
by 10 min incubation at 56°C. Eight hundred μl of abso-
lute ethanol was added followed by pulse-vortex mixing.
After centrifugation, the mixture was washed by following
the protocols and solutions of the manufacturer. DNA
was eluted by adding 30 to 60 μl of elution buffer (10mM
TrisCl, pH 9.0, 0.5mM EDTA).
Polymerase Chain Reaction (PCR)
For LMP1 30-bp deletion analysis, 2 μl of DNA, 1X PCR
buffer, 1.5mM MgCl2, 200 nM dNTPs mix, 500 nM L30F
(primer sequence 5'-GTCATAGTAGCTTAGCTGAAC-3')
and L30R primers (primer sequence 5'-GAAGAGGTT-
GAAAACAAAGGA-3) [28] and 0.05U/μl Taq DNA
polymerase (Fermentas, Canada) were used to carry out
the PCR amplification. The PCR was performed by using
T-Gradient Thermoblock (Biometra, Germany) with ini-
tial denaturation at 95°C for 5 min followed by 35 cycles
of denaturation at 95°C for 1 min, annealing at 51.2°C
for 1 min and extension at 72°C for 1 min. The final
extension step was carried out at 72°C for 5 min. For XhoI
restriction site analysis, the primers used were X1.1
(primer sequence 5'-ATGGAACACGACCTTGAGAGG-3')
and X1.2 (primer sequence 5'-AACAGTAGCGCCAAGAG-
CAG-3') [13] and the annealing temperature was modi-
fied to 55.9°C. The PCR product for the XhoI
polymorphism analysis was purified using the GENE
ALL™ PCR SV kit (General Biosystem, Korea) following
the manufacturer's recommendations.
XhoI restriction enzyme digestion of PCR products
The purified PCR product was subjected to digestion with
restriction enzyme XhoI (Fermentas, USA). Wild type
B95.8 served as the positive control. The reaction mixture
consisted of 1X buffer R, 0.05U/μl of restriction enzyme
XhoI, 12 μl of purified PCR product and 5 μl of sterile dis-
tilled water was added to make up a total volume of 20 μl.
The reaction was incubated at 37°C for 3 hours and sub-
jected to heat inactivation at 50°C for 20 min.
Agarose gel electrophoresis
The digested PCR product was analysed using gel electro-
phoresis with 3% low melt Agarose II gel (Amresco,
Ohio). Electrophoresis was performed at 80 volts for 45
min in 1X TAE buffer. The gel was then stained with ethid-
ium bromide and visualised by using FluorChem Imaging
System (Alpha Innotech, USA). The Gene Ruler™ DNA
ladder mix (Fermentas, USA) was used as the standard
DNA molecular weight marker.
DNA sequencing
To confirm that the amplicons harbour LMP-1 30-bp dele-
tion, two amplicons from NPC tissue DNA were ran-
domly selected for sequencing by using the BigDye®
Terminator v3.1 sequencing kit and ABI PRISM®  377
Genetic Analyser. Primers used for sequencing were L30F
and L30R. The sequencing results were compared with the
other EBV strains to determine the difference in the nucle-
otide sequences, if any.
Statistical analysis
Fisher's exact test was used to analyse the association
between the presence of the LMP1 30-bp deletion variant
and XhoI polymorphism with population characteristics
and histological data. Data were processed with the SPSS
programme for Windows, version 13.0 (SPSS Inc., Chi-
cago, Illinois).World Journal of Surgical Oncology 2008, 6:18 http://www.wjso.com/content/6/1/18
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Results
Detection of the EBV LMP1 gene 30-bp deletion
The region spanning the LMP1 30-bp deletion was suc-
cessfully amplified from 34/42 NPC cases and 8/10 non-
malignant tissues. Among the 34 amplifiable cases, 47.1%
(16/34) were from undifferentiated carcinoma (UC,
WHO type III) samples, followed by 35.3% (12/34) in
non-keratinizing carcinoma (NKC, WHO type II) and
17.6% (6/34) in keratinizing squamous cell carcinoma
(SCC, WHO type I) samples. The LMP1 30-bp deletion
variant (as represented in Lane C, Figure 1) was found in
19/34 cases (55.9%) of which 13 were undifferentiated
carcinoma (type III) and 5 were non-keratinizing carci-
noma (Type II) and 1 was keratinized squamous carci-
noma (type I). The 30-bp deletion variant was not present
in any of the 8 amplifiable non-malignant tissues (Table
1). A statistical different was found between the presence
of LMP1 30-bp deletion in NPC versus non-malignant
nasopharyngeal tissues (p = 0.005 Fisher's Exact test).
As for the plasma samples, 82.9% (29/35) of plasma sam-
ples were amplifiable for LMP1 30-bp deletion analysis.
Seven out of 29 cases (24.1%) harboured the 30-bp dele-
tion (as represented in Lane 1, Figure 1) whereas, 22/29
(75.9%) specimens retained the wild type variant (repre-
sented in Lane 2–4, Figure 1). Interestingly, of these 7 pos-
itive cases, concurrent expression of both variants with
and without the LMP1 30-bp deletion were observed in 5
cases (5/29;17.2%) as represented in Lane 2, Figure 2
(Table 1).
The presence of LMP1 30-bp deletion was confirmed by
sequencing two samples, namely NPC 1 and NPC 2
(Table 2). The samples which harboured the LMP1 30-bp
deletion as determined by DNA sequencing were used as
the controls in this study. Besides the 30-bp deletion, both
NPC 1 and 2 showed the following substitutions: Q334R,
L338S, and S366T between codon 327 and 383 of the car-
boxyl terminal of LMP1 as shown in Table 2. A point
mutation from A → T at 168295 was also found in these
two isolates. In addition, NPC 2 harboured one addi-
tional change at codon 335 (GGC → GAC) resulting in an
amino acid change from glycine (G) to aspartic acid (D).
This was also detected in the China 1 and DV strain.
Histological type and population characteristics including
age, gender and race corresponding to the presence or
absence of LMP1 30-bp deletion were compared. Statisti-
cal analysis showed that the presence of 30-bp deleted var-
iant in NPC tissues between the keratinizing squamous
cell carcinoma (SCC, WHO type I) and undifferentiated
carcinoma (UC, WHO type III) was significantly different
(p = 0.011; Table 3). Comparison of the races showed that
88.9% of Chinese (16/18) had the LMP1 30-bp deletion
variant, followed by 20% Malay (3/15). The presence of
LMP1 30-bp deletion from Chinese was statistically
Table 1: 30-bp deletion and XhoI polymorphism in NPC biopsies and plasma, and non-malignant nasopharyngeal tissues
NPC tissues % (n = 42) Non-malignant nasopharyngeal 
tissues % (n = 10)
NPC plasma % (n = 35)
Analysis
LMP1 30-bp deletion
Frequency detected by PCR 81.0 (34/42) 80 (8/10) 82.9 (29/35)
With deletion 55.9 (19/34) 0 24.1 (7/29)
No deletion 44.1 (15/34) 100 (8/8) 75.9 (22/29)
With and without deletion 0 (0/34) 0 (0/8) 17.2 (5/29)
XhoI polymorphism
Frequency detected by PCR 92.9 (39/42) 80 (8/10) 85.7 (30/35)
Loss of XhoI site 87.2 (34/39) 0 36.7 (11/30)
Retention of XhoI site 12.8 (5/39) 100 (8/8) 63.3 (19/30)
Co-existence of 30-bp deletion and XhoI-loss 59.4 (19/32) 0 (0/8) 25.0 (6/24)
Representative agarose gel electrophoresis of the LMP1  exon 3 amplicons with and without the 30-bp deletion Figure 1
Representative agarose gel electrophoresis of the 
LMP1 exon 3 amplicons with and without the 30-bp 
deletion. M-100 bp DNA ladder marker, N-No template 
control, B-LMP1 exon 3 from B95.8, C-NPC tissue that dis-
play 30-bp deletion (product size= 156-bp), 1-NPC plasma 
that display 30-bp deletion (product size = 156-bp), 2–4-NPC 
plasma without the 30-bp deletion (product size = 186-bp).World Journal of Surgical Oncology 2008, 6:18 http://www.wjso.com/content/6/1/18
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higher than Malay in NPC tissues (p < 0.05) (Table 3). No
statistical difference was found with age and gender in
NPC tissues (age, p = 0.289; gender, p = 1.000).
Detection of the XhoI polymorphism in the exon 1 of 
LMP1 gene
As summarized in Table 1, XhoI polymorphic region was
successfully amplified in 92.9% (39/42) NPC and 80%
(8/10) of non-malignant tissues. PCR with primers X1.1
and X1.2 generates a 113-bp amplicon which harbours
the XhoI polymorphic region. If XhoI site is present, restric-
tion enzyme digest of the 113-bp amplicon yields two
DNA fragments of 67 and 46-bp. The loss of XhoI restric-
tion site was detected in 87.2% (34/39) of NPC tissues
samples (represented in lane 2, Figure 3). All 8 of the
amplifiable non-malignant tissues samples retained the
XhoI restriction site (represented in lane 3, Figure 3). The
loss of XhoI restriction site was statistically higher in the
NPC tissues compared to the non-malignant tissues (p <
0.05; Fisher's Exact test). As for the plasma sample, the
region spanning the XhoI restriction site in exon 1 was suc-
cessfully amplified in 85.7% (30/35) of the samples. The
loss of XhoI site was found in 11/30 cases (36.7%), (rep-
resented in lane 5, Figure 3).
The presence of EBV variant with loss of XhoI restriction
site with population characteristics and histological type
are as summarised in Table 3. Statistical difference was
found only for the histological type and race. In this study,
Table 2: Comparison of deduced amino acid sequences in the LMP1 exon 3 in NPC1 and NPC2
Nucleotide 168342
Codon 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
B 9 5 . 8 VENKGGDQGP P LMTDGGGG
CAO A R S
China I R D S
NPC 1 R S
NPC 2 R D S
Nucleotide 168342
Codon 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364
B 9 5 . 8 HSHDSGHGGGDPHL PTL L L
C A O ******
C h i n a  I ******
N P C  1 ******
N P C  2 ******
Nucleotide 168342
Codon 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383
B 9 5 . 8 GS SGSGGDDDDPHGPVQL S
CAO T
China I T
NPC 1 T
NPC 2 T
Asterisks (*) indicate amino acid deletion. Previously published prototype sequences were obtained from Fennewald et al., 1984 (B95.8).
Hu et al., 1991 (CAO), Sung et al., 1998 (China 1). NPC 1 and NPC 2 are isolates from NPC tissue samples subjected to DNA sequencing.
Representative gel electrophoresis of LMP1 amplicons from  NPC plasma Figure 2
Representative gel electrophoresis of LMP1 ampli-
cons from NPC plasma: M-100 bp DNA ladder marker, 
N-No template control, B-LMP1 exon 3 from B95.8, 1-NPC 
plasma without 30-bp deletion (product size = 186-bp), 2-
NPC plasma with coexistence of wild type and 30bp deletion.W
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) Table 3: Association between population characteristics and histological type with 30-bp deletion and XhoI-loss studiesin NPC tissue and plasma samples
Number of 30-bp deletion in LMP1 (%) Number of Loss of Xho I site (%) Co-existence of 30-bp deletion 
and Xho I-loss in NPC tissues
NPC tissues P value NPC plasma P value NPC tissue P value NPC plasma P value Number of 
co-existence
P value
Clinicopathological 
Features
Sex
Male 14/25 (56.0) 1.000 7/26 (26.9) 1.000 24/27 (88.9) 0.615 9/24 (37.5) 0.529 14/23 (60.9) 0.689
Female 4/8 (50.0)¶ 0/2 (0.0)¥ 9/11 (81.8)€ 0/2 (0.0)Ω 4/8 (50.0)
Age
<50 years 6/14 (42.9) 0.289 4/15 (26.7) 1.000 12/15 (80.0) 0.630 4/16 (25.0) 0.234 6/13 (46.2) 0.274
>50 years 11/17 (64.7)§ 2/11 (18.2)∞ 19/21 (90.5)∂ 5/10 (50.0)Ω 11/16 (68.8)Φ
Race
Malay 3/15 (20.0) Malay vs. India, 
p = 1.000 Malay vs. 
Chinese, p < 0.05* 
Chinese vs. India, 
p = 0.158
1/10 (10.0) 0.363 14/19 (73.7) Malay vs. Chinese, 
p = 0.046*
3/11 (27.3) 0.689 3/14 (21.4) Malay vs. India, 
p = 1.000
Chinese 16/18 (88.9) 5/17 (29.4)Ø 19/19 (100.0) 7/17 (41.2)Ψ 16/17 (94.1) Malay vs. Chinese, 
p < 0.050*
Indian 0/1 (0.0) 1/1 (100.0) 0/1 (0.0)
Histological type
Type I – Keratinizing 
squamous cell carcinoma 
(SCC)
1/6 (16.7) SCC vs. NKC, 
p = 0.600
0/2 (0.0) SCC vs. NKC, 
p = 1.000
2/5 (40.0) SCC vs. NKC, 
p = 0.063
0/2 (0.0) SCC vs. NKC, 
p = 0.429
1/4 (25.0) SCC vs. NKC, 
p = 1.000
Type II – Non-
keratinizing carcinoma 
(NKC)
5/12 (41.7) SCC vs. UC, 
p = 0.011*
2/6 (33.3) SCC vs. UC, 
p = 1.000
14/16 (87.5) SCC vs. UC, 
p = 0.006* 
4/6 (66.7) SCC vs. UC, 
P = 1.000
5/12 (41.7) SCC vs. UC, 
p = 0.061
Type III – 
Undifferentiated 
carcinoma (UC)
13/16 (81.3) NKC vs. UC, 
p = 0.050
1/8 (12.5)¤ NKC vs. UC, 
p = 0.538
18/18 (100.0) NKC vs. UC, 
p = 0.214
1/10 (10.0)θ NKC vs. UC, 
p = 0.056
13/16 (81.3) NKC vs. UC, 
p = 0.050
Statistical significance of the difference was analyzed using Fisher's Exact test, (*) indicates statistical significance (p < 0.05). ¶Data was only available for 33 out of 34 cases.§Data was only available for 31 out of 34 
cases. ¥Data was only available for 28 out of 29 cases. ∞Data was only available for 26 out of 29 cases. ØData was only available for 27 out of 29 cases. ¤Data are only available for 16 out of 29 cases. €Data was only 
available for 38 out of 39 cases. ∂The data was only available for 36 out of 39 cases. ΩData was only available for 26 out of 30 cases. ΨData was only available for 28 out of 30 cases. θData was only available for 18 
out of 30 cases for NPC plasma samples. Data was only available for 31 out of 32 cases for NPC tissues. ΦData was only available for 29 out of 32 cases for NPC tissues.World Journal of Surgical Oncology 2008, 6:18 http://www.wjso.com/content/6/1/18
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the loss of XhoI restriction site was detected in 40.0% (2/
5) of the keratinizing squamous cell carcinoma (SCC,
WHO type I) samples, 87.5% (14/16) of the non-kerati-
nizing carcinoma (NKC, WHO type II) samples, and
100.0% (18/18) of the undifferentiated carcinoma (UC,
WHO type III) samples (Table 3). Statistical analysis
showed a significant difference for the presence of XhoI
polymorphism in NPC tissues between the SCC type and
UC type (p = 0.006; Table 3). Loss of XhoI restriction site
was found in 100.0% of Chinese (19/19) and Indian (1/
1), followed by 73.7% Malay (14/19). The presence of
EBV variant with XhoI-loss in NPC tissues from Chinese
was statistically higher than Malay (p = 0.046).
Co-existence of the LMP1 30-bp deletion and XhoI-loss in 
NPC
Table 1 shows 19/32 NPC tissues and 6/24 plasma sam-
ples harboured both LMP1 30-bp deletion and XhoI loss.
Table 3 shows the association between the coexistence of
the LMP1 30-bp deletion and loss of XhoI in 19/32
(59.4%) of NPC tissues. Statistical significance was only
found in NPC tissues between Chinese and Malays. No
significant relationship was found between co-expression
of both variants and histological type in NPC.
Discussion
In this study, the presence of a high frequency of the LMP1
30-bp deletion in EBV isolates from NPC tissues as com-
pared to non-malignant tissues is in agreement with pre-
vious reports [21,27,28]. Interestingly, although the 30-
bp deleted variant was not detected in non-malignant tis-
sues, it has been found in lymphoblastoid cell lines
derived from Chinese healthy chronic carriers [3]. The
authors suggested that the presence of variant LMPl in
NPC simply reflects the overall prevalence of this poly-
morphism in EBV strains infecting the general Chinese
population.
The incidence rate of the 30-bp deletion variant in this
study is lower than that compared to three other reports
from Malaysia, whereby, positive rates of 97%, 91% and
100% were reported [27,29,30]. Other studies from NPC
endemic areas such as Southern China and Taiwan
showed 75% and more than 90% deleted LMP1-positive
cases, respectively [18,31-33]. The reasons for the lower
incidence rate in this study is unclear.
Another difference in our data is that coexistence of dual
variants with and without 30-bp deletion in plasma but
not NPC tissues from another group of patients. This dif-
fers from other studies, whereby, existence of dual vari-
ants in 1.5% (8/542) and 16% (4/25) NPC tissues have
been previously reported [26,27]. To the best of our
knowledge, this is the first report to show the co-presence
of both variants in plasma from NPC patients. It is most
likely that EBV in plasma is derived from the tumour as
shown by Chan et al. (2003) [34]. We are not able to con-
firm this in the current study as we have not determined
the LMP1 30-bp status with paired tissue samples.
In our study, the DNA sequence of two of the amplicons
from NPC tissues spanning the LMP1 C-terminal region,
namely NPC1 and NPC2 was determined. In addition to
the 30-bp deletion, NPC2 but not NPC1 harboured a
mutation at codon 335. This sequence resembles the
China 1 [31] and DV-Asp335 strain [32]. The codon 335,
which is located outside the known functional domains
(CTAR1 and CTAR2) is involved in the nuclear factor
(NF)-κβ signaling and has been postulated to be involved
in protein turnover [35]. Comparison of the LMP1 vari-
ants isolated from healthy individuals in Hong Kong
showed that 80% of these individuals harboured the 30-
bp deletion but the majority of them (73%) do not have
the substituted amino acid at codon 335. The prevalence
of codon 335 mutation in our NPC patients in Malaysia
has not yet been determined.
Similar to the LMP1 C-terminus, a number of sequence
variations have been found in the short cytoplasmic N-ter-
minus. Among them is the loss of an XhoI restriction site
in exon 1 which is commonly reported in Southern
China. This was first described in the CAO strain, the nude
mouse passaged Chinese NPC EBV isolate. The presence
of Xho-I loss variant in our tissues samples is comparable
to other endemic areas such as in Southern China and Tai-
Xho I restriction digest analyses of NPC and non-malignant  tissues, and plasma samples from NPC patients Figure 3
Xho I restriction digest analyses of NPC and non-
malignant tissues, and plasma samples from NPC 
patients. M-100-bp DNA ladder marker, B-B95.8 control 
that with XhoI restriction site (two bands of 67 and 46-bp 
after XhoI digestion), 1-NPC tissue sample with XhoI restric-
tion site, 2-NPC tissue sample with loss of XhoI site show 
undigested 113-bp product, 3-Non-malignant nasopharyngeal 
tissue that retained XhoI restriction site, 4&6-NPC plasma 
samples with loss of XhoI site show undigested 113-bp prod-
uct, 5-NPC plasma samples with XhoI restriction site.World Journal of Surgical Oncology 2008, 6:18 http://www.wjso.com/content/6/1/18
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wan, whereby, 97–100% of NPC cases harboured loss of
XhoI restriction site [20,36]. This polymorphism was also
present in NPC from Alaska and in some of the NPC sam-
ples from Caucasian Americans but was absent in NPC
and healthy controls in Africa [19,37]. The loss of an XhoI
restriction site has been associated with Chinese NPC, and
it has been considered to be a specific tumour marker in
NPC biopsies and throat washes [18,21,27,38]. However,
to date, little is known about the efficiency of malignant
transformation by this variant.
In this study, NPC tissues showed a higher percentage of
XhoI-loss as compared to plasma samples from another
group of patients. The high incidence of XhoI-loss is com-
parable to another study, whereby, an incidence rate of
93% (25/27) of NPC biopsies was reported [27]. No
reports on XhoI-loss variants have been reported for
plasma samples.
In order to further understand the role of LMP1 variants
in NPC pathogenesis, we performed statistical analysis
between either the presence of 30-bp deleted LMP1 or
XhoI-loss with histological type and population character-
istics such as gender, age and race. Our data suggested that
EBV-associated NPC mutations in LMP1 occurred at dif-
ferent rates in different racial groups. This is consistent
with another study, whereby, the LMP1 30-bp deletion
variant was found to be predominant in Inuit origin pop-
ulations [39] and Chinese [21] which were the two groups
who are especially prone to NPC [1].
Our study showed that EBV LMP1 30-bp deletion and
XhoI-loss variants were found to be predominant in undif-
ferentiated carcinomas (Type III) compared to keratiniz-
ing squamous cell carcinoma (Type I). This suggests that
the variants may play a crucial role in carcinogenesis of
undifferentiated carcinomas (Type III). No correlation
with XhoI-loss and histological type has been reported.
Comparison with published data showed that there is no
relationship between histological type and LMP1 30-bp
deletion variant in NPC [26] which differs from our study.
EBV isolates with the LMPl 30-bp deletion have been pref-
erentially found in histologically aggressive forms of
Hodgkin's disease [40,41]. However, findings by Khanim
et al. (1996) [37] do not support the association of LMP1-
deleted EBV with aggressive HD. The possibility that
LMP1 deletions may contribute to the malignant behav-
iour of NPC cases constitutes an attractive hypothesis that
deserves further investigation.
Interestingly, majority of our NPC tissues (19/32; 59.4)
showed the coexistence of both the 30-bp deletion and
the loss of XhoI restriction site. This resembles the CAO,
C1510, China 1 and DV2 isolates from NPC endemic
areas. The clinical significance of coexistence of both vari-
ants is unknown. The 30-bp deletion alone is not a prog-
nosticator for overall survival [26,28] and distant
metastasis [26]. Further investigation is required to deter-
mine if coexistence of the two variants is correlated with
worse prognosis and overall survival of our patients. We
also found a higher incidence rate of coexistence of 30-bp
deletion and XhoI loss variants in Chinese versus Malay
patients. However, there was no relationship between
coexistence of these variants with histological type. The
implications of these findings are unclear and require fur-
ther investigation.
Conclusion
In conclusion, LMP1 30-bp deletion and loss of XhoI site
was found in NPC tissues but not non-malignant tissues.
Dual variants of LMP1 were only found in plasma from
NPC patients. A significant relationship was found
between LMP1 30-bp deletion and loss of XhoI site
between histological type and race. The prevalence of cer-
tain EBV strains as represented by LMP1 sequence varia-
tion in NPC, particularly the 30-bp deletion in C-terminus
and XhoI polymorphism in N-terminus in LMP1 as shown
in this study as well as previous studies, may have unique
functional properties, which determine disease associa-
tion or development. Further studies with these variants
are needed to elucidate the LMP1 signalling pathway, and
to assess the contribution of LMP1 sequence variation to
the pathogenesis of EBV-associated tumours, particularly
in NPC.
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